|
1
|
Manciulli T, Spinicci M, Rossetti B,
Antonello RM, Lagi F, Barbiero A, Chechi F, Formica G, Francalanci
E, Alesi M, et al: Safety and efficacy of outpatient treatments for
COVID-19: Real-life data from a regionwide cohort of high-risk
patients in Tuscany, Italy (the FEDERATE cohort). Viruses.
15(438)2023.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bhimraj A, Morgan RL, Shumaker AH, Baden
L, Cheng VCC, Edwards KM, Gallagher JC, Gandhi RT, Muller WJ,
Nakamura MM, et al: Infectious diseases society of America
guidelines on the treatment and management of patients with
COVID-19. Clin Infect Dis: Apr 27, 2020 (Epub ahead of print).
|
|
3
|
Terkes V, Lisica K, Marusic M, Verunica N,
Tolic A and Morovic M: Remdesivir treatment in moderately Ill
COVID-19 patients: A retrospective single center study. J Clin Med.
11(5066)2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Frediansyah A, Nainu F, Dhama K, Mudatsir
M and Harapan H: Remdesivir and its antiviral activity against
COVID-19: A systematic review. Clin Epidemiol Glob Health.
9:123–127. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Liang C, Tian L, Liu Y, Hui N, Qiao G, Li
H, Shi Z, Tang Y, Zhang D, Xie X and Zhao X: A promising antiviral
candidate drug for the COVID-19 pandemic: A mini-review of
remdesivir. Eur J Med Chem. 201(112527)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Beigel JH, Tomashek KM, Dodd LE, Mehta AK,
Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, et
al: Remdesivir for the treatment of covid-19-final report. N Engl J
Med. 383:1813–1826. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Goldman JD, Lye DCB, Hui DS, Marks KM,
Bruno R, Montejano R, Spinner CD, Galli M, Ahn MY, Nahass RG, et
al: Remdesivir for 5 or 10 days in patients with severe covid-19. N
Engl J Med. 383:1827–1837. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Angamo MT, Mohammed MA and Peterson GM:
Efficacy and safety of remdesivir in hospitalised COVID-19
patients: a systematic review and meta-analysis. Infection.
50:27–41. 2022.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Georgakopoulou VE, Papalexis P, Sanos C,
Bitsani A, Garmpi A, Damaskos C, Garmpis N, Gkoufa A, Chlapoutakis
S, Sklapani P, et al: Asymptomatic SARS-CoV-2 infection in an
unvaccinated 97-year-old woman: A case report. Biomed Rep.
15(107)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Georgakopoulou VE, Basoulis D, Voutsinas
PM, Makrodimitri S, Samara S, Triantafyllou M, Eliadi I,
Karamanakos G, Papageorgiou CV, Anastasopoulou A, et al: Factors
predicting poor outcomes of patients treated with tocilizumab for
COVID-19-associated pneumonia: A retrospective study. Exp Ther Med.
24(724)2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kokkoris S, Gkoufa A, Maneta E, Doumas G,
Mizi E, Georgakopoulou VE, Sigala I, Dima E, Papachatzakis I,
Ntaidou TK, et al: Older adults with severe coronavirus disease
2019 admitted to intensive care unit: prevalence, characteristics
and risk factors for mortality. Minerva Anestesiol. 88:803–814.
2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Gkoufa A, Maneta E, Ntoumas GN,
Georgakopoulou VE, Mantelou A, Kokkoris S and Routsi C: Elderly
adults with COVID-19 admitted to intensive care unit: A narrative
review. World J Crit Care Med. 10:278–289. 2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Gottlieb RL, Vaca CE, Paredes R, Mera J,
Webb BJ, Perez G, Oguchi G, Ryan P, Nielsen BU, Brown M, et al:
Early Remdesivir to prevent progression to severe covid-19 in
outpatients. N Engl J Med. 386:305–315. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kintrilis N and Galinos I: Outpatient
intravenous remdesivir to prevent progression to severe COVID-19:
An observational study from a Greek hospital. Recent Adv Antiinfect
Drug Discov: Mar 31, 2023 (Epub ahead of print).
|
|
15
|
Aye TT, Myat K, Tun HP, Thiha P, Han TM,
Win YY and Han AMM: Early initiation of remdesivir and its effect
on oxygen desaturation: A clinical review study among high-risk
COVID-19 patients in Myanmar. J Family Med Prim Care. 11:4644–4649.
2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gáspár Z, Szabó BG, Ábrahám A, Várnai Z,
Kiss-Dala N, Szlávik J, Sinkó J, Vályi-Nagy I and Lakatos B:
Outcomes of high-risk adult outpatients treated with early
remdesivir therapy during the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) omicron era: Experiences from the
national centre of Hungary. Naunyn Schmiedebergs Arch Pharmacol.
396:1857–1862. 2023.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Mazzitelli M, Trunfio M, Sasset L,
Scaglione V, Ferrari A, Mengato D, Gardin S, Bonadiman N,
Calandrino L, Agostini E and Cattelan AM: Risk of hospitalization
and sequelae in patients with COVID-19 treated with 3-day early
remdesivir vs. controls in the vaccine and Omicron era: A real-life
cohort study. J Med Virol. 95(e28660)2023.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Rajme-López S, Martinez-Guerra BA,
Zalapa-Soto J, Román-Montes CM, Tamez-Torres KM, González-Lara MF,
Hernandez-Gilosul T, Kershenobich-Stalnikowitz D, Sifuentes-Osornio
J, Ponce-de-León A and Ruíz-Palacios GM: Early outpatient treatment
with remdesivir in patients at high risk for severe COVID-19: A
prospective cohort study. Open Forum Infect Dis.
9(ofac502)2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Panagopoulos P, Petrakis V, Trypsianis G
and Papazoglou D: Early 3-day course of remdesivir in vaccinated
outpatients with SARS-CoV-2 infection. A success story. J
Chemother. 34:550–553. 2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Meini S, Bracalente I, Bontempo G, Longo
B, De Martino M and Tascini C: Early 3-day course of remdesivir to
prevent progression to severe Covid-19 in high-risk patients with
hospital-acquired SARS-CoV-2 infection: Preliminary results from
two Italian outbreaks. New Microbiol. 45:304–307. 2022.PubMed/NCBI
|
|
21
|
Takahashi Y, Wakita H, Ishihara T, Okazaki
H, Ito A, Iwata M, Sonoda S and Doi Y: Short-course remdesivir for
healthcare-associated COVID-19: Case series from a non-acute care
hospital. J Infect Chemother. 29:95–97. 2023.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Adjei S, Hong K, Molinari NM,
Bull-Otterson L, Ajani UA, Gundlapalli AV, Harris AM, Hsu J, Kadri
SS, Starnes J, et al: Mortality risk among patients hospitalized
primarily for COVID-19 during the omicron and delta variant
pandemic periods-United States, April 2020-June 2022. MMWR Morb
Mortal Wkly Rep. 71:1182–1189. 2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Colaneri M, Amarasinghe N, Rezzonico L,
Pieri TC, Segalini E, Sambo M, Roda S, Meloni F, Gregorini M,
Rampino T, et al: Early remdesivir to prevent severe COVID-19 in
recipients of solid organ transplant: A real-life study from
Northern Italy. Int J Infect Dis. 121:157–160. 2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Belli LS, Fondevila C, Cortesi PA, Conti
S, Karam V, Adam R, Coilly A, Ericzon BG, Loinaz C, Cuervas-Mons V,
et al: Protective role of Tacrolimus, deleterious role of age and
comorbidities in liver transplant recipients with covid-19: Results
from the ELITA/ELTR multi-center european study. Gastroenterology.
160:1151–1163.e3. 2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Gatti M, Rinaldi M, Bussini L, Bonazzetti
C, Pascale R, Pasquini Z, Faní F, Pinho Guedes MN, Azzini AM,
Carrara E, et al: Clinical outcome in solid organ transplant
recipients affected by COVID-19 compared to general population: a
systematic review and meta-analysis. Clin Microbiol Infect.
28:1057–1065. 2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Mikulska M, Testi D, Russo C, Balletto E,
Sepulcri C, Bussini L, Dentone C, Magne F, Policarpo S, Campoli C,
et al: Outcome of early treatment of SARS-CoV-2 infection in
patients with haematological disorders. Br J Haematol. 20:628–639.
2023.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Passamonti F, Cattaneo C, Arcaini L, Bruna
R, Cavo M, Merli F, Angelucci E, Krampera M, Cairoli R, Della Porta
MG, et al: Clinical characteristics and risk factors associated
with COVID-19 severity in patients with haematological malignancies
in Italy: A retrospective, multicentre, cohort study. Lancet
Haematol. 7:e737–e745. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
D'Abramo A, Vita S, Maffongelli G,
Beccacece A, Agrati C, Cimini E, Colavita F, Giancola ML, Cavasio A
and Nicastri E: Spallanzani COVID-19 Case Investigation Team.
Clinical management of patients with B-cell depletion agents to
treat or prevent prolonged and severe SARS-COV-2 infection:
Defining a treatment pathway. Front Immunol.
13(911339)2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Liu Y, Du X, Chen J, Jin Y, Peng L, Wang
HHX, Luo M, Chen L and Zhao Y: Neutrophil-to-lymphocyte ratio as an
independent risk factor for mortality in hospitalized patients with
COVID-19. J Infect. 81:e6–e12. 2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Mathioudakis N, Zachiotis M, Papadakos S,
Triantafyllou M, Karapanou A, Samara S, Karamanakos G, Spandidos
DA, Papalexis P, Damaskos C, et al: Onodera's prognostic
nutritional index: Comparison of its role in the severity and
outcomes of patients with COVID-19 during the periods of alpha,
delta and omicron variant predominance. Exp Ther Med.
24(675)2022.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Karakoyun I, Colak A, Turken M, Altin Z,
Arslan FD, Iyilikci V, Yilmaz N and Kose S: Diagnostic utility of
C-reactive protein to albumin ratio as an early warning sign in
hospitalized severe COVID-19 patients. Int Immunopharmacol.
91(107285)2021.PubMed/NCBI View Article : Google Scholar
|
